MARCH 2021 BEST OF CROI
CROI talks covered in Chiva best of CROI meeting 29th March.
The talks from CROI referenced in the Chiva meeting are available as webcast at: http://www.croiwebcasts.org/y/2021
TALK 1: DR LIZ WHITTAKER – SARS-COV-2 IN CHILDREN
Asymptomatic SARS-CoV-2 children have lower infectivity and intact memory responses – Nicola Cotugno
Elucidating SARS-CoV-2 T cell responses in paediatric COVID-19 and MIS-C – Vidisha Singh
High specific immune response and activation in children with COVID-19 – Maria Rafaella Petrara
High and persistent neutralising antibodies in children recovered from COVID-19 – Francesco Bonfante
Robust humoral responses to SARS-CoV-2 infection in children – Carolina Garrido
Microbiological features and follow-up of neonates born to mothers with COVID-19 – Itziar Carrasco
Safety and efficacy of remdesivir in a COVID-19 pediatric population – Flor Munoz
SARS-CoV-2 persists in intestinal tissue up to 7 months after symptom resolution – Minami Tokuyama
ACE2 is expressed throughout the intestines, particularly in the small bowel – Suarez-Farinas
Severe COVID-19 is fueled by disrupted gut barrier integrity – Leila Gron
Intestinal permeability and microbial translocation are increased in severe COVID – Natanjya Utay
Humoral responses against the SARS-CoV-2 Spike – Andres Finzi
Longitudinal antibody responses to SARS-CoV-2 and emerging variants – Katie Doores
T cell immunity in SARS-CoV-2 natural infection and following vaccination – Julie McElrath
TALK 2: DR HERMIONE LYALL – HIV IN PREGNANCY AND NEONATES
HIV treatment in Pregnancy: Beyond prevention of vertical transmission – Shahin Lockman
PREP during pregnancy and breastfeeding – John Kinuthia
ARVs and ART for newborns and infants: a last frontier – Mo Archary
COVID-19 in high risk S.African pregnancies with and without HIV – L De Waard
Dolphin-2 final results – Thokozile Malaba
Antepartum weight gain and adverse pregnancy outcomes in IMPAACT 2010 – Risa Hoffman
Safety/Efficacy of DTG vs EFV, TDF vs TAF in pregnancy/postpartum IMPAACT 2010 – Lameck Chinula
Adverse pregnancy outcomes among HIV-infected women exposed to isoniazid in Brief-TB trial – Amita Gupta
NRTI-sparing strategy to prevent perinatal HIV transmission ANRS 168 Monogest trial – Laurent Mandelbrot
ART, adherence during and post breastfeeding using TDF in hair – Teacler Nematadzira
National evaluation of Malawi’s PMTCT program: 24-month HIV-exposed infant outcomes – Monique van Lettow
Preventing vertical HIV transmission in the UK: successes and emerging challenges – Helen Peters
Preterm birth, breastfeeding, antenatal ARV regimen and 24-month HIV-Free survival – Mary Fowler
TALK 3: DR ANNA TURKOVA – DOLUTEGRAVIR – LATEST DATA ON EFFICACY AND TOXICITY
Dolutegravir based ART is superior to NNRTI/PI-based in children and adolescents – Anna Turkova
Nucleosides and darunavir/dolutegravir in Africa (NADIA) trial: 48 weeks primary outcome – Nicholas Paton
Dolutegravir vs darunavir-r based ART in very advanced patients: 48 weeks results – Jose Miro
D/C/F/TAF vs DTG/ABC/3TC for initial treatment in HIV+adults: a randomized study – Daniel Podzamczer
Durable efficacy of DTG + 3TC in GEMINI-1 & -2: year 3 subgroup analyses – Chloe Orkin
Switching to DTG/3TC is noninferior to TAF-based 3- or 4-drug regimen for 96 weeks: TANGO subgroup analyses – Paul Benson
Impact of M184V on the virological efficacy of switch to DTG/3TC in real life – Maria Santoro
Incident diabetes associated with INSTI initiation – Jane O’Halloran
Predicted 10-year risks of cardiovascular disease and diabetes in the ADVANCE trial – Laura Hindley
Dolutegravir and viral load suppression among peadiatric patients in care in Zambia – Shilpa Iyer
PK and safety of high-dose rifampicin in TB/HIV coinfected patients on EFV or DTG – Christine Sekaggya-Wiltshire
Weight gain on DTG-containing ART – Science Spotlight Session
IMPAACT 2010: Weight gain in pregnant women and post delivery – Risa Hoffman #176, Lameck Chinula #177
Weight gain after switch to InSTI or TAF – Frank Patella #504 (US)
Association bw newer antiretrovirals and increase in BMI in RESPOND – Bansi-Matharu Loveleen #507 (UK)
Weight gain after DTG-based ART start in Kenya – Kaseem Bourgi #509
Obesity is highly prevalent in people of African ancestry living with HIV in the UK – Liza Hamzah #508
In vitro model to assess antiretroviral therapy on adipocyte biology – R. Taylor Pickering # 514
Integrase inhibitors target mitochondria in brown adipocytes disrupting thermogenesis – Ikrak Jung # 515
TALK 4: DR ALASDAIR BAMFORD – NEW DRUGS AND TREATMENT STRATEGIES
Novel antiretroviral therapies in clinical development – Alexandra Calmy
Potent antiviral activity of lenacapavir in phase 2/3 in heavily ART-experienced PWH – Sorana Segal-Mara
Resistance profile of MK_8507 a novel NNRTI suitable for weekly oral treatment – Tracy Diamond
Model-informed dose selection for islatravir/MK-8507 oral once-weekly phase 2B study – Bhargava Kandala
Week 96 analysis of viral blips from a phase 2B trial of islatravir and doravirine – Chloe Orkin
Phase 2a proof-of-concept trial of next-generation maturation inhibitor GSK’254 – Christoph Spinner
Four-year outcomes of B/F/TAF in Treatment-Naïve Adults – Kimberly Workowski
Week 96 efficacy and safety of long-acting cabotegravir + rilpivirine every 2 months – Atlas-2M
Randomised trial of resistance testing for virological failure in sub-Saharan Africa – Mark Siedner
A simple and safe approach to HCV-treatment – Sunil Solomon
Current antiretroviral treatment among people with HIV in care in the US – Jimmy Ma
IMPAACT 2014 24-week pK and safety of doravirine/3TC/TDF in adolescents with HIV-1 – Ann Melvin
Switching efavirenz to rilpivirine in virologically suppressed adolescents with HIV – Wanatpreeya Phongsamart
Adequate daclatasvir exposures in children 14-35kg with available adult formulations – Tim Cressey
Advances in peadiatric TB diagnosis, treatment and prevention in CLHIV and HEU – Nicole Salazar-Austen
